This post was originally published on this site Delivering higher doses of radiation therapy over a shorter time period — an approach called stereotactic body radiation therapy (SBRT) — does not worsen side effects in men with localized prostate cancer, compared to conventional radiation therapy, a Phase 3 trial shows. The study also suggests that…
Conditions
Conditions
$53M NIA Grant Will Test Alzheimer’s Care in Real-world Settings
This post was originally published on this site The National Institute on Aging (NIA) has awarded a five-year grant expected to total $53.4 million to Brown University and Hebrew SeniorLife to lead the creation and management of a research incubator to test Alzheimer’s and dementia care interventions in real-world settings. Called the NIA Imbedded Pragmatic AD/ADRD Clinical…
My Sister’s Breast Cancer Diagnosis Taught Us an Important Lesson About Caregiving
This post was originally published on this site October is Breast Cancer Awareness Month, but what does that have to do with Alzheimer’s disease and caregiving? Nothing, except that women make up the majority of caregivers in the United States. This means that over 60 percent of caregivers are susceptible to breast cancer. Breast cancer…
Verzenio-Faslodex Combo Prolongs Survival of Women with Advanced Breast Cancer, Phase 3 Trial Shows
This post was originally published on this site Verzenio (abemaciclib) in combination with Faslodex (fulvestrant) prolongs the survival of women with HR-positive, HER2-negative, advanced or metastatic breast cancer who had been treated previously with endocrine therapy, a Phase 3 clinical trial shows. The findings were presented in a late-breaking presentation, “MONARCH 2: Overall survival of…
Lenvima-Keytruda Combo Maintains Positive Results in Advanced Endometrial Cancer
This post was originally published on this site Combination therapy with Lenvima (lenvatinib) and Keytruda (pembrolizumab) continues to show promising antitumor results in patients with advanced endometrial cancer, the most common cancer of the uterus, according to the final results of the KEYNOTE-146/Study 111 trial. The combo was generally well-tolerated, and no new safety signals…
CLR 131 Works to Halt Cancer Growth and Lower Tumor Volume in DLBCL, Early Phase 2 Data Show
This post was originally published on this site Cellectar Biosciences’ investigational radiotherapeutic compound, CLR 131, effectively halted cancer progression and reduced tumor size in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), interim data of a Phase 2 trial shows. These results were part of the oral presentation “Interim Evaluation of a Targeted Radiotherapeutic, CLR 131,…
Adding Veliparib Extended Time Without Disease Progression in Metastatic Ovarian Cancer, Phase 3 Trial Finds
This post was originally published on this site Using veliparib in combination with chemotherapy as first-line and then maintenance therapy post-surgery significantly extended the time without disease progression in women with newly diagnosed metastatic high-grade serous (HGS) ovarian cancer, according to Phase 3 trial results. The research was presented in the session, “VELIA/GOG-3005: Integration of…
Bone Marrow Macrophages Could Predict Resistance to Velcade, Study Suggests
This post was originally published on this site The multiple myeloma therapy Velcade (bortezomib) can induce the formation of pro-inflammatory macrophages — a kind of white blood cell — that promote the growth of myeloma tumors, Israeli researchers found. The presence of such cells in the bone marrow could help explain why some myelomas turn…
NIA Launches Research Centers to Advance Drug Discovery in Alzheimer’s
This post was originally published on this site To advance the pipeline for innovative therapeutics in Alzheimer’s (AD), the National Institute on Aging (NIA) will invest an expected $73 million over five years in two new translational research centers. The centers will be funded through the NIA’s Alzheimer Centers for the Discovery of New Medicines program,…
Veliparib-Chemo Combo Prolongs Survival Without Disease Progression in Certain Advanced Breast Cancer Patients, Phase 3 Trial Shows
This post was originally published on this site Veliparib in combination with chemotherapy significantly prolongs survival without disease progression in women with metastatic HER2-negative breast cancer with BRCA mutations, compared with women on chemotherapy alone, a Phase 3 trial shows. The trial’s findings were presented in a session, titled “Phase 3 study of veliparib with…
Mycophenolate Mofetil May Be Effective as Alternative Sarcoidosis Treatment, Small Study Suggests
This post was originally published on this site Mycophenolate mofetil (MMF) significantly reduced disease symptoms in people with sarcoidosis, and helped to reduce their daily dose of corticosteroids, a small study suggests. The study, “Mycophenolate mofetil as an alternative treatment in sarcoidosis,” was published in the journal of Pulmonary Pharmacology & Therapeutics. Sarcoidosis is characterized by an over-reactive…
Aplidin Prolongs Survival and Time to Disease Progression in Heavily Treated Multiple Myeloma Patients, Phase 3 Trial Shows
This post was originally published on this site Aplidin (plitidepsin) in combination with dexamethasone significantly prolonged the survival and time to disease progression or death in heavily treated patients with relapsed or refractory multiple myeloma compared to patients taking dexamethasone alone, a Phase 3 trial shows. The trial’s findings were reported in the study, “Randomized…